Quantcast
Last updated on April 18, 2014 at 17:24 EDT

XCHC Releases Worldwide Growth Guidance For Its Cannabinoid Treatment Centers and Formulations Targeting Critical Human Ailments, Company Acts on Own Guidance

February 21, 2013

DALLAS, Feb. 21, 2013 /PRNewswire/ — X-Change Corp. (NASDAQ OTC: XCHC), a patient based U.S. company targeting critical and non-critical ailments through the use of Cannabinoid based formulations, extracts, and products through multiple Phytiva Brand product lines and solutions, is pleased to release its analysis of the worldwide market potential for medical Cannabinoid treatments of critical ailments and acute disease.

The amount of money needed on a worldwide basis for treating critical and non-critical ailments is unnecessary, wasteful, and inhumane. The Company’s near-term, global mission is to advance affordable and effective treatment solutions for a wide variety of ailments, as outlined below, using Cannabinoids. A comparative cost analysis shows a dramatic difference in treatment cost for most ailments between the status quo and the Company’s approach. Therefore, the Company intends to use this massive differential, which is essentially a large profit base, through which to expand operations by opening multiple treatment facilities locally and internationally at a rapid rate.

The Company has already publicly launched two initiatives with its Phytiva Brand European Cannabinoid product line and its Cannabinoid treatment-based facility development agreement with the Maliseet Nation in Eastern Canada.

These are two examples of the Company’s targeted investments demonstrating a solid commitment to innovation in seizing opportunities in the quickly emerging Cannabinoid based treatment market. And the market opportunities are substantial:

    AIDS              $12.6           In 2010, $12.6 billion treatment
                                      market. TechNavio's analysts forecast
                                      the global HIV drug market to reach
                                      $15.5 billion by 2014.
    Alzheimer's        $8.3           The global Alzheimer's disease
                                      treatment market was valued at $8.3
                                      billion in 2010 and estimated to be
                                      $9.0 billion by 2016.
    Anti-             $50.0           With annual estimates nearing $50
     Aging                            billion a year, the market for global
                                      Anti-Aging products expected to reach
                                      $291.9 billion by 2015.
                Overall sales in the Asthma and COPD
                                      drug market worth $25 billion in 2008,
                                      increasing to an estimated $26 billion
                                      in 2009. By 2014, this market is
                                      projected to increase to $31 billion,
                                      for a 5-year compound annual growth
    Asthma            $25.0           rate (CAGR) of 3.3%.
    Arthritis         $35.0           Global market for arthritis drugs
                                      valued at $35 billion in 2008.
    Cancer            $75.0           Global sales of cancer drugs expected
                                      to grow at a compounded annual rate of
                                      12 to 15 percent, reaching $75 to $80
                                      billion this year.
    Chronic     Pain Management globally recorded sales
     Pain                             of $22.0 billion in 2010; rising at a
     Management                       compound annual growth rate (CAGR) of
                                      8.9% market value is set to contract
                      $22.0           to $18.7 billion by 2016.
                In 2009, the Diabetes treatment market
                                      generated worldwide sales of over $25
                                      billion.  Datamonitor expects the
                                      antidiabetics market will grow to
                                      $34.8 billion in 2019 for the seven
    Diabetes          $25.0           major markets.
     Digestive  The global market for medical enzymes
     Diseases                         is estimated at $6 billion in 2010.
                                      The market is growing at a compounded
                                      annual rate (CAGR) of 3.9%, to reach
                                      $7.2 billion in 2015. Therapeutic
                                      enzymes are the biggest segment in
                                      terms of revenues generated. This
                                      sector was valued at $5.3 billion in
                                      2010 and is expected to increase at a
                                      3.6% compound. Enzymes used in
                                      molecular research expected to
                                      experience the fastest compound annual
                                      growth rate (CAGR) of 6.2%, over the
                                      study period. This sector was valued
                                      at $546 million in 2010 and expected
                       $6.0           to reach $739 million by 2015.
    Glaucoma          $14.0           Over $14 billion in 2009. The global
                                      Glaucoma pharmaceuticals market is
                                      projected to exceed $3.35 billion by
                                      2015.
    High              $25.0           The prescription drug market for the
     Blood                            treatment of Hypertension is estimated
     Pressure                         to continue to rise in value from $25
                                      billion today.
    Influenza         $28.0           In 2009, the global market for
                                      antiviral drugs attained total sales
                                      of over $28 billion.
     Multiple   The Multiple Sclerosis (MS) treatments
     Sclerosis                        market is one of the largest for CNS
                                      disorders, with total pharmaceutical
                                      revenues of over $8 billion in 2009.
                                      Revenues for MS treatments will rise
                       $8.0           significantly from 2010 to 2025.
    PTSD              $72.0          $72 billion from top ten drug sales - and rising.

X-Change Corp. President & CEO Robert Kane stated, “Global demand for Cannabinoid based treatments is growing exponentially and is reaching into the hundreds of billions of dollars. The demand for Cannabinoid treatments is at an all-time high, as clinicians, scientists, and patients are discovering or rediscovering their efficacy. The treatment cost-based comparisons give us an inherent advantage within the current market structures, and thus we believe that our mission will succeed: the Company mission is to become one of the leading providers of Cannabinoid treatments. Through our partnerships and associations, we believe that the Company is already growing at such a substantial rate that we will have a truly positive impact on the healthcare industry and on fundamental human health treatments and options.”

About Phytiva Brand Product Lines

Phytiva expects to develop and launch various innovative product lines. The first is the Phytiva Brand European Line, which is an inventive line that is a hybrid of a proven, existing product line that has been well-managed and conservatively-run for over a decade with a Cannabinoid based product line, utilizing the unique and potent benefits of Cannabinoids. Phytiva’s revolutionary formulations target not just the symptom, but also the cause. Cannabinoids and their sources constitute an ideal base for therapeutic solutions and have been utilized for centuries in skin and other remedies.

In the near term, Phytiva strives to be one of the quintessential cosmeceutical and nutraceutical brands in the world. As cosmetics and nutrition are personal, over-the-counter markets, they continuously evolve with the introduction of new formulations and products, creating a multibillion-dollar global market opportunity. The Company believes that Phytiva’s lines will capture a substantial and profitable portion of that market, as Phytiva becomes a household name.

About The X-Change Corporation

X-Change Corp. is U.S. Boutique Company whose niche is Cannabinoid based extracts and products that target medical cannabis, cosmeceutical, nutraceutical, and social usage solutions through multiple Phytiva Brand product lines, products, and services. These new Phytiva lines will be launched with Cannabinoid based formulations through the launching of a combination of retail and wholesale products, medical cannabis dispensaries, cannabis research in clinics and laboratories, as announced for example with the Maliseet Nation in Canada, and other legal state and foreign grow operations, on a jurisdiction by jurisdiction approved basis.

Forward Looking Statements

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as “anticipate,” “seek,” intend,” “believe,” “plan,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. X-Change Corp. does not undertake any duty nor does it intend to update the results of these forward-looking statements.

X-Change Corp.

President & CEO

Robert Kane

info@phytiva.com

www.phytiva.com

1.866.326.5595

SOURCE X-Change Corp.


Source: PR Newswire